325 related articles for article (PubMed ID: 2521415)
1. The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias.
Miles WM; Heger JJ; Minardo JD; Klein LS; Prystowsky EN; Zipes DP
Am Heart J; 1989 Jan; 117(1):112-21. PubMed ID: 2521415
[TBL] [Abstract][Full Text] [Related]
2. [Electrophysiologic effects of enoximone].
Brembilla-Perrot B; Beurrier D; Bock F; Danglas P
Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():69-74. PubMed ID: 2147838
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic effects of enoximone in patients with congestive heart failure.
Hohnloser SH; Zehender M; Geibel A; Meinertz T; Just H
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S29-32. PubMed ID: 2480482
[TBL] [Abstract][Full Text] [Related]
4. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.
Kereiakes D; Chatterjee K; Parmley WW; Atherton B; Curran D; Kereiakes A; Spangenberg R
J Am Coll Cardiol; 1984 Nov; 4(5):884-9. PubMed ID: 6238076
[TBL] [Abstract][Full Text] [Related]
5. Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure.
Naccarelli GV; Gray EL; Dougherty AH; Hanna JE; Goldstein RA
Am J Cardiol; 1984 Sep; 54(6):600-4. PubMed ID: 6475780
[TBL] [Abstract][Full Text] [Related]
6. Ethmozine: electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias.
Dorian P; Echt DS; Mead RH; Lee JT; Lebsack CS; Winkle RA
Am Heart J; 1986 Aug; 112(2):327-33. PubMed ID: 3526852
[TBL] [Abstract][Full Text] [Related]
7. A dose-response study of intravenous enoximone in congestive heart failure.
Erbel R; Meyer J; Diefenbach C; Delorme G; Bourdarias JP; Vernant P; Lellouche D; Mattioli G; Barbieri A; Installe E
Am J Cardiol; 1987 Aug; 60(5):31C-36C. PubMed ID: 2956865
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines.
Van Veldhuisen DJ; Crijns HJ; Girbes AR; Tobé TJ; Wiesfeld AC; Lie KI
Am J Cardiol; 1991 Nov; 68(11):1194-202. PubMed ID: 1683146
[TBL] [Abstract][Full Text] [Related]
9. Heart rate variability in patients suffering from structural heart disease and decreased AV-nodal conduction capacity. Insights into the formation of heart rate variability.
Schwab JO; Eichner G; Schmitt H; Schrickel J; Yang A; Balta O; Lüderitz B; Lewalter T
Z Kardiol; 2004 Mar; 93(3):229-33. PubMed ID: 15024591
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation.
Khalife K; Zannad F; Brunotte F; Belhadj K; Juilliere Y; Iannascoli F; Gilgenkrantz JM
Am J Cardiol; 1987 Aug; 60(5):75C-79C. PubMed ID: 2956874
[TBL] [Abstract][Full Text] [Related]
12. MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.
Rubin SA; Tabak L
J Am Coll Cardiol; 1985 Jun; 5(6):1422-7. PubMed ID: 3158690
[TBL] [Abstract][Full Text] [Related]
13. [Enoximone: hemodynamic effect in patients with cardiac insufficiency].
de Langenhagen B; Bouchoucha H; Scholl JM; Hennetier G; Benacerraf A; Achard F; Bock F
Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():19-25. PubMed ID: 2147830
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias.
Sung RJ; Juma Z; Saksena S
Am Heart J; 1983 May; 105(5):811-9. PubMed ID: 6189384
[TBL] [Abstract][Full Text] [Related]
15. [Enoximone, vasodilator and/or inotropic agent in congestive cardiac insufficiency? Hemodynamic and ventriculographic study of 20 cases].
Durrieu C; Rochoux G; Coste P; Le Goff G; Besse P
Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():43-50. PubMed ID: 2147834
[TBL] [Abstract][Full Text] [Related]
16. Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients.
Waxman HL; Groh WC; Marchlinski FE; Buxton AE; Sadowski LM; Horowitz LN; Josephson ME; Kastor JA
Am J Cardiol; 1982 Nov; 50(5):1066-74. PubMed ID: 6291368
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic effects of chronic amiodarone therapy in patients with ventricular arrhythmias.
Finerman WB; Hamer A; Peter T; Weiss D; Mandel WJ
Am Heart J; 1982 Nov; 104(5 Pt 1):987-96. PubMed ID: 7137016
[TBL] [Abstract][Full Text] [Related]
18. Comparison of electrophysiologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia.
Gambhir DS; Bhargava M; Nair M; Arora R; Khalilullah M
Indian Heart J; 1996; 48(2):133-7. PubMed ID: 8682552
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias.
Saksena S; Klein GJ; Kowey PR; Calvo RA; Boccadamo R; Brown JE; Sharma AD; Gadhoke A; Olukotun AY
Am J Cardiol; 1987 Feb; 59(4):307-12. PubMed ID: 3812280
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of enoximone during intravenous infusion.
Winkle RA; Smith NA; Ruder MA; Mead RH; Lebsack C; Bekele T; Kates RE; Rubin J; Okerholm R
Int J Cardiol; 1990 Jul; 28 Suppl 1():S1-2. PubMed ID: 2145232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
